Source link : https://www.newshealth.biz/health-news/daratumumab-quadruplet-supported-transplant-ineligible-mm/
In the treatment of patients with newly diagnosed multiple myeloma (MM) who are not eligible for stem cell transplant or are transplant-deferred, adding subcutaneous daratumumab to bortezomib/lenalidomide/dexamethasone (D-VRd) significantly improves minimal residual disease (MRD) outcomes among patients, the first results from the phase 3 CEPHEUS trial showed. “CEPHEUS is the first phase 3 daratumumab trail […]
Author : News Health
Publish date : 2024-10-01 13:02:15
Copyright for syndicated content belongs to the linked Source.
Categories